The Board

Born 1969. Board member since 2020.

Education and experience: Martin holds an MBA at the Stockholm School of Economics. He is the co-founder of A3P Biomedical AB and one of the company’s largest owners. Martin has more than 15 years’ experience of working in interface between academia and industry. His former positions include Investment Manager with the venture capital firm Litorina Kapital and Manager with Arthur D. Little.

Born 1966. Board Member since 2021.

Education and experience: Cecilia has a B.Sc. in Finance and Economics at the Stockholm School of Economics. Cecilia has extensive experience of operational work in senior positions in several industries. She is a Board member of Flerie Invest AB and Neonode Inc, as well as an Advisory Board Member of the European Patient Safety Foundation (EUPSF). She previously served as CEO and Board member of Bactiguard AB, a Swedish company focused on infection prevention with a global footprint, and thus has good insight into the Life Science industry at a growth company active in an international context.

Born 1961. Board member since 2021.

Education and experience: Henrik has a M.D. and Ph.D. in Oncology at Umeå University. Henrik is a professor of cancer epidemiology at Karolinska Institutet, where he leads a research group with 35 researchers focused on prostate cancer. Henrik is a co-founder of A3P Biomedical, one of the company’s largest owners and a leading expert in prostate cancer.

Born 1966. Board member since 2023.

Education and experience: Thomas von Koch holds a master’s degree in Economics at the Stockholm School of Economics. He has 30 years of experience in entrepreneurship, finance and leadership. After a couple of years at Investor AB, he joined the global investment giant EQT in 1994 as one of the first team members. Thomas von Koch was CEO and Managing Partner of EQT from 2014 to 2019 and is today chairman of EQT Asia Pacific. He is since 2019 (also during the period 2005 to 2013) chairman of the board of the Swedish medical technology company Bactiguard AB, a company he co-founded and remains the main owner of.

Born 1966. Board member since 2022.

Education and experience: Mark Quick is a partner in Flerie which invests in venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges. He is also a board member of several portfolio companies including Empros, Microbiotica, Bohus Biotech and is also chairman of the board of Anacardio. Prior to Flerie, Mark Quick was responsible for Recipharm’s M&A operations and was part of the leadership committee. Before that he spent time at ICI, Medeva, Celltech and UCB in various business development and supply chain roles. He also has an MBA from The Open University.

Born 1959. Board member since 2023.

Education and experience: Jeroen Tas holds a master’s degree in Computer Science and Business Administration from the Vrije University, Amsterdam. He is an experienced innovation leader who, through his entrepreneurship and competence in large-scale digital transformation, information technology and digital health technology, develops companies. Jeoren Tas was Chief Innovation and Strategy Officer at Philips from 2017 to 2021. Prior to Philips, he was co-founder and President, COO and Vice Chairman of Mphasis, which was acquired by HP in 2006.